Psilocybin
Optimi Health enters $1.2M psilocybin distribution agreement
The mushroom cultivator will be supplying a private client for clinical research purposes
The post Optimi Health enters $1.2M psilocybin distribution…
Vancouver-based Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) has secured a $1.2 million psilocybin supply agreement with a private client that will be using the company’s mushrooms for clinical research purposes.
Optimi announced the new agreement on Thursday and says it will be providing additional details in the coming months.
“This is a big day for Optimi. To be selected as the singular supply entity in the sector capable of scaling to help fulfill the needs of our client reflects our ability to deliver substantial value to the research community and our shareholders,” said Optimi’s CEO Bill Ciprick.
Read more: Optimi Health secures MDMA and psilocybin distribution agreement in Australia
Read more: Optimi Health submits clinical trial application after developing proprietary MDMA drug
Optimi is authorized by Health Canada through controlled drugs and substances regulations to conduct comprehensive drug research and formulate psychedelic compounds like natural GMP-grade psilocybin and MDMA for clinical research purposes. This allows them to produce and supply these substances for scientific investigation.
Optimi received an amendment from Health Canada permitting the company to produce MDMA in addition to psilocybin last August.
“We will have more to say in the coming months; however, for now we are focused on execution as we work to establish a long-term, mutually beneficial relationship,” said Bryan Safarik, Optimi’s Chief Operational Officer.
The company’s 20,000-square-foot cultivation facilities in Princeton B.C. are the largest of their kind worldwide. The air inside those facilities is as clean as an operating room, those entering them must come in through an airlock and all of the walls are cleaned on a nightly basis to prevent contamination.
Optimi plans on producing other psychedelics in the future but is primarily concerned with MDMA and psilocybin production for the time being.
The news follows Optimi securing its first international supply agreement with Mind Medicine Australia at the beginning of March. The company will be supplying its GMP-certified psilocybin and MDMA to the Australian non-profit in a long-term agreement aimed at combatting PTSD and treatment-resistant depression commencing once Australia’s authorized prescriber scheme takes effect in July.
The company also submitted a clinical trial application for a novel variety of MDMA it developed called OPTI-MHCL in February.
Optimi’s shares rose by 20 per cent on Thursday to $0.27 on the Canadian Securities Exchange.
rowan@mugglehead.com
The post Optimi Health enters $1.2M psilocybin distribution agreement appeared first on Mugglehead Magazine.
psilocybin mdma psychedelic depression ptsd psychedelics shares cse mind medicine optimi health optimi health canada research-
Psilocybin6 days ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics6 days ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics6 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics6 days ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Law & Regulation6 days ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psychedelics6 days ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psychedelics7 days ago
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research
-
Psychedelics6 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID